miR-132 may also regulate tau alternative splicing in vitro by targeting poly-pyrimidine tract-binding protein 2 (PTBP2), and its levels correlate with tau splicing defects in patients with progressive supranuclear palsy (PSP) cases (Smith et al., 2011). This evidence concerns the gene MAPT and Classical progressive supranuclear palsy.